On March 5, 2014, Registrant disseminated the Press Release attached to this
Current Report as Exhibit 99.1, which announced, among other things, that
researchers at Registrant's majority owned subsidiary, Exosome Sciences, Inc.
("ESI") have successfully isolated brain-specific biomarkers associated with a
variety of neurodegenerative disorders. The Registrant believes that these
discoveries could have implications in the diagnosis, monitoring and treatment
of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and
Traumatic Brain Injury (TBI).

The foregoing description of the Press Release does not purport to be complete
and is qualified in its entirety by the Press Release attached as Exhibit 99.1
hereto. Readers should review the Press Release for a complete understanding of
its content and the matters announced and described in the Press Release.